3'-Azido-3'-deoxy-5-methyl-beta-L-uridine manufacturers
|
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine Basic information |
| Product Name: | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine | | Synonyms: | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine;3’-Azido-3’-deoxy-5-methyl-β-L-uridine;3'-Azido-3'-deoxy-5-methyl-b-L-uridine;3’-Azido-3’-deoxy-5-methyl-beta-L-uridine;N-[(3-ethoxyphenyl)methyl]-4-[(4-methylphenyl)methyl]-5-oxomorpholine-3-carboxamide | | CAS: | 2095417-10-8 | | MF: | C10H13N5O5 | | MW: | 283.24 | | EINECS: | | | Product Categories: | | | Mol File: | 2095417-10-8.mol |  |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine Chemical Properties |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine Usage And Synthesis |
| Uses | 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 3'-Azido-3'-deoxy-5-methyl-beta-L-uridine Preparation Products And Raw materials |
|